Fate Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FATE Nasdaq 2836 www.fatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fate Therapeutics, Inc.

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates - Aug 6th, 2026 7:50 am
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Aug 3rd, 2026 2:05 pm
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Jul 9th, 2026 2:52 pm
Sector Update: Healthcare Stocks Softer Late Afternoon - Jul 9th, 2026 1:49 pm
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate - Jul 9th, 2026 6:30 am
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting - Jul 6th, 2026 6:30 am
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - Jul 1st, 2026 2:05 pm
Fate Therapeutics Appoints Laura Hamill to Board of Directors - Jun 15th, 2026 6:30 am
H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT - Jun 10th, 2026 12:22 pm
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting - Jun 4th, 2026 6:30 am
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting - Jun 1st, 2026 6:30 am
Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely? - May 30th, 2026 8:45 am
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - May 21st, 2026 6:30 am
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates - May 13th, 2026 7:40 am
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates - May 13th, 2026 6:30 am
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting - May 11th, 2026 6:30 am
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates - May 7th, 2026 5:05 pm
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - May 6th, 2026 8:00 am
Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates - May 6th, 2026 7:30 am
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 - May 5th, 2026 6:30 am